filings.toolsItem 1A. Risk Factors
2K characters. Original on sec.gov · Markdown
Item 1A. Risk Factors
Through the quarterly period covered by this report, there have been no material changes to the risk factors disclosed in Item 1A to Part I of Linde's Annual Report on Form 10-K for the year ended December 31, 2024.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Purchases of Equity Securities- Certain information regarding purchases made by or on behalf of the company or any affiliated purchaser (as defined in Rule 10b-18(a)(3) under the Securities Exchange Act of 1934, as amended) of its ordinary shares during the quarter ended March 31, 2025 is provided below:
| Period | Total Number of Shares Purchased (Thousands) | Average Price Paid Per Share | Total Numbers of Shares Purchased as Part of Publicly Announced Program (1) (Thousands) | Approximate Dollar Value of Shares that May Yet be Purchased Under the Program (2) (Millions) | |||||||||||||||||||
| January 2025 | 375 | $ | 429.97 | 375 | $ | 11,746 | |||||||||||||||||
| February 2025 | 981 | $ | 460.22 | 981 | $ | 11,294 | |||||||||||||||||
| March 2025 | 1,061 | $ | 458.90 | 1,061 | $ | 10,808 | |||||||||||||||||
| First Quarter 2025 | 2,417 | $ | 454.95 | 2,417 | $ | 10,808 |
(1)On October 23, 2023, the company's board of directors approved the repurchase of $15.0 billion of its ordinary shares ("2023 program") which could take place from time to time on the open market (and could include the use of 10b5-1 trading plans), subject to market and business conditions. The 2023 program began on October 23, 2023 and will terminate on the earlier of the date as the maximum authority under the 2023 program is reached or the board terminates the 2023 program.
(2)As of March 31, 2025, the company repurchased $4.2 billion of its ordinary shares pursuant to the 2023 share repurchase program. As of March 31, 2025, $10.8 billion of share repurchases remain authorized under the 2023 program.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Previous: Item 1. Legal Proceedings · Next: Item 5. Other Information